What's Happening?
Madrigal Pharmaceuticals has entered into a licensing agreement with Arrowhead Pharmaceuticals to acquire ARO-PNPLA3, an RNAi candidate targeting a genetic driver of metabolic dysfunction-associated steatohepatitis (MASH). Madrigal will pay $25 million
upfront and up to $1 billion in total for the asset. ARO-PNPLA3 complements Madrigal's existing MASH therapy, Rezdiffra, by targeting the PNPLA3 I148M mutation, a key contributor to MASH progression. Phase 1 data showed significant reductions in liver fat, and Madrigal is in discussions with the FDA to design a Phase 2 program.
Why It's Important?
This deal underscores Madrigal's commitment to expanding its therapeutic offerings for MASH, a liver disease with significant unmet medical needs. By acquiring ARO-PNPLA3, Madrigal aims to enhance its treatment portfolio and address different aspects of the disease. The agreement highlights the growing interest in RNAi technology as a promising approach for targeting genetic contributors to complex diseases. For Arrowhead, the partnership allows the company to leverage Madrigal's expertise in MASH while focusing on its core cardiometabolic programs.
What's Next?
Madrigal plans to advance ARO-PNPLA3 into Phase 2 clinical trials, pending FDA alignment on the study design. The company will continue to explore combination therapies with Rezdiffra and other investigational siRNA assets. The success of this program could pave the way for further collaborations and innovations in RNAi-based therapies for liver diseases. Stakeholders will be watching closely to see how Madrigal's expanded portfolio impacts the competitive landscape and patient outcomes in the MASH treatment space.
